The research, conducted in collaboration with the University of Copenhagen and Bispebjerg-Frederiksberg Hospital, shows that HERV-K activates when cells face metabolic stress. This reactivation triggers a cascade of pro-inflammatory responses, providing a potential biological link between obesity, insulin resistance, and accelerated aging. Clinical data confirmed these findings by detecting elevated levels of the virus in human plasma samples from volunteers with obesity.

J. Robert Coleman, CEO of HERVolution Therapeutics, stated that the data positions HERV-K at the center of the biology connecting chronic inflammation and cellular senescence. The company intends to leverage these results to expand its immunotherapeutic platform, which targets HERV-derived antigens, beyond oncology. Their lead program, IPT-001, is currently moving toward human trials to test whether neutralizing these viral sequences can mitigate disease progression in both metabolic and cancer-related contexts.